EAM Investors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

EAM Investors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-48,875	Closed	-$1.13M	–	402
2023 Q1	$1.13M	Sell	48,875 -53,132	-52%	-$1.27M	0.22%	220
2022 Q4	$2.67M	Sell	102,007 -21,903	-18%	-$485K	0.55%	51
2022 Q3	$2.44M	Buy	123,910 +9,941	+9%	+$199K	0.53%	64
2022 Q2	$1.99M	Buy	+113,969	New	+$1.79M	0.49%	69

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EAM Investors's KDNY Position: Q2 2023 in Review

EAM Investors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 48,875 shares — an estimated $1.13M sold.

EAM Investors first reported a position in KDNY in Q2 2022 and held it in 4 quarters. The position peaked at $2.67M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

EAM Investors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
EAM Investors sold 48,875 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.13M.
EAM Investors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
EAM Investors's Chinook Therapeutics, Inc. Common Stock position peaked at $2.67M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.